stockrowAmylyx Pharmaceuticals, Inc.
AMLX Healthcare Drug Manufacturers Specialty & Generic
Amylyx Pharmaceuticals, Inc.’s revenue for fiscal 2024 (year ended December 2024) was $87.4 million, down 77.1% from fiscal 2023.
- Revenue
- −100.6%
- EPS
- +15.2%
- Free cash flow
- −24.5%
Quarter to June 2026, against a year earlier
Follow AMLX
Alert me
Amylyx Pharmaceuticals, Inc. (AMLX) Net income
Amylyx Pharmaceuticals, Inc.'s net income for fiscal 2025 was −$144.7M, compared with −$301.7M in fiscal 2024. Over the twelve months to 30 June 2026 it was −$152.1M. Over the past ten years it has ranged from −$301.7M (fiscal 2024) to $49.3M (fiscal 2023); the current reading is higher than 43% of that period. Amylyx Pharmaceuticals, Inc. ranks 75th of 84 Drug Manufacturers Specialty & Generic companies by net income.
Net income, annual
Embed this chart
Annual newest first
| Period | Net income | Change |
|---|---|---|
| FY2025 | −$144.7M | — |
| FY2024 | −$301.7M | — |
| FY2023 | $49.3M | — |
| FY2022 | −$198.4M | — |
| FY2021 | −$87.9M | — |
| FY2020 | −$42.3M | — |
| FY2017 | $0.00 | — |
Quarterly newest first
| Period | Net income | Change |
|---|---|---|
| Jun 2026 | −$43.4M | — |
| Mar 2026 | −$41.3M | — |
| Dec 2025 | −$33.0M | — |
| Sep 2025 | −$34.4M | — |
| 19 more quarters | Free account |
Against its own ten years
Net income against peers
| Company | Net income |
|---|---|
| HCM HUTCHMED (China) Limited Sponsored ADR compare | $967.7M |
| SUPN Indivior Pharmaceuticals Inc. compare | $450.0M |
| PBH Prestige Consumer Healthcare Inc. compare | $155.1M |
| LQDA Liquidia Corporation compare | $138.6M |
| RGC Regencell Bioscience Holdings Limited compare | −$14.0M |
| HIMS Hims & Hers Health, Inc. compare | −$142.0M |
| AMLX Amylyx Pharmaceuticals, Inc. | −$152.1M |
| TRLV Trulieve Cannabis Corp. compare | −$446.6M |
| PRGO Perrigo Company plc compare | −$1.8B |
What Net income is
Net Income tells an investor how much profit a company kept in a period after every cost, interest charge and tax.
Reported line item
More on AMLX
- Revenue
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- The full statement